Program
Pneumococcal 21-Valent Conjugate Vaccine
Also written as “V116”, “PCV21 vaccine” and “PCV21”.
Its studies are mostly in Pneumococcal Infections · Pneumonia, Pneumococcal · Anemia, Sickle Cell, led by 2 companies.
Drug pagePneumococcal 21-Valent Conjugate Vaccine: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 110 open or running | phase 3since May 23, 2022 | Nov 18, 2019 | none ahead |
| Sanofi | 77 open or running | phase 3since Oct 10, 2024 | Oct 10, 2024 | Dec 1, 2026phase 3 · NCT06838000 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 10, 2024First study: phase 3 study in Pneumococcal InfectionsFirst studyNCT06838000 · 1,268 enrolled · United States, Estonia, Poland and more
- Dec 11, 2024Phase 3 study in Pneumococcal ImmunizationNCT06736041 · 1,714 enrolled · United States, Australia, Honduras and more
- Feb 7, 20252 phase 3 studies in Pneumococcal ImmunizationNCT06824194, NCT06824181
- May 8, 2025Phase 3 study in Pneumococcal ImmunizationNCT06975878 · 1,092 enrolled · Belgium, Czechia, Estonia and more
- Nov 19, 2025Phase 3 study in Anemia, Sickle CellNCT07247188 · 100 planned · United States, Dominican Republic
- Jan 15, 2026Phase 3 study in Pneumococcal InfectionsNCT07348692 · 2,195 planned · United States, Honduras, Puerto Rico and more
Ahead
- Dec 1, 2026Primary completion: phase 3 study in Pneumococcal InfectionsNCT06838000
- Jan 7, 2027Primary completion: phase 3 study in Anemia, Sickle CellNCT07247188
- May 17, 2027Primary completion: phase 3 study in Pneumococcal ImmunizationNCT06736041
- Jun 7, 2027Primary completion: phase 3 study in Pneumococcal InfectionsNCT07348692
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A pneumococcal conjugate vaccine containing 21 different strains of the bacterium Streptococcus pneumoniae, that is used for the prevention of pneumococcal disease”NCIt, by rule
“Pneumococcal 21-Valent Conjugate Vaccine”name, by rule
Studies
All 7 Sanofi leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07348692Pneumococcal Infections · United States, Honduras, Puerto Rico and more | 3 | Recruiting | Jun 7, 2027 | 2,195 |
| NCT07247188Anemia, Sickle Cell · United States, Dominican Republic | 3 | Recruiting | Jan 7, 2027 | 100 |
| NCT06975878Pneumococcal Immunization · Belgium, Czechia, Estonia and more | 3 | Active, not recruiting | Aug 25, 2027 | 1,092 |
| NCT06824194Pneumococcal Immunization · United States, Honduras, Mexico and more | 3 | Active, not recruiting | Oct 22, 2027 | 2,360 |
| NCT06824181Pneumococcal Immunization · United States, Chile, Mexico and more | 3 | Active, not recruiting | Sep 10, 2027 | 580 |
| NCT06736041Pneumococcal Immunization · United States, Australia, Honduras and more | 3 | Active, not recruiting | May 17, 2027 | 1,714 |
| NCT06838000Pneumococcal Infections · United States, Estonia, Poland and more | 3 | Active, not recruiting | Dec 1, 2026 | 1,268 |
How it is read
Names in the registry
- “V116”, 11 entries
- “PCV21 vaccine”, 5 entries
- “PCV21”, 2 entries
Conditions, from the studies’ own filings
- Pneumococcal Infections, 10 studies
- Pneumonia, Pneumococcal, 3 studies
- Anemia, Sickle Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.